文献速递骨质疏松与代谢性骨病

印度绝经后骨质疏松女性地舒单抗个体化治疗:骨转换标志物与体重指数对给药间隔的预测作用

Personalizing denosumab therapy in postmenopausal Indian women with osteoporosis: predictive role of bone turnover markers and body mass index in determining dosing interval.
PubMed 文献 · Osteoporos Int · 2025-09-29

该前瞻性观察研究纳入56例DXA确诊骨质疏松的印度绝经后女性,起始地舒单抗60 mg皮下注射,根据6个月时血清β-CTX水平决定后续注射时机。较低基线β-CTX和较低BMI独立预测地舒单抗延迟给药超过6个月,两组均未观察到新发椎体骨折。

要点

  • 延迟组基线β-CTX为497 pg/mL,低于标准组的794 pg/mL(p < 0.001)。
  • 延迟组BMI为23.29 ± 2.77 kg/m²,低于标准组的25.59 ± 3.03 kg/m²(p = 0.005)。
  • 较低基线β-CTX(OR 0.99;95% CI 0.98-1.00;p = 0.027)和较低BMI(OR 0.60;95% CI 0.40-0.89;p = 0.012)独立预测延迟给药。

核心结论

  • 较低的基线骨转换和较低的BMI可能有助于识别可安全将地舒单抗给药延迟至6个月以上的印度绝经后女性。
  • 这些发现为初步结果,尚未确立长期安全性或有效性;在临床实践中采用延长给药间隔前,需要进行随访时间更长的进一步研究。

研究设计与样本

  • 前瞻性观察性研究,纳入56例DXA确诊骨质疏松的印度绝经后女性,起始地舒单抗60 mg皮下注射。
  • 参与者均未接受过既往抗骨吸收治疗;部分参与者正在补充维生素D,与其较高的基线血清25-羟基维生素D水平一致。
  • 6个月时测量血清β-CTX水平以指导后续注射时机,分为标准组(6个月时给药)和延迟组(若β-CTX <300 pg/mL则推迟至6个月后给药)。
  • 分析基线骨转换标志物、BMI和骨折结局,采用多变量逻辑回归识别延迟给药的预测因素。

主要发现

  • 28例女性接受延迟注射,中位间隔为9.5个月。
  • 与标准组相比,延迟组基线β-CTX水平显著更低(497 vs. 794 pg/mL;p < 0.001)。
  • 与标准组相比,延迟组BMI更低(23.29 ± 2.77 vs. 25.59 ± 3.03 kg/m²;p = 0.005)。
  • 多变量分析显示,较低基线β-CTX(OR 0.99;95% CI 0.98-1.00;p = 0.027)和较低BMI(OR 0.60;95% CI 0.40-0.89;p = 0.012)独立预测地舒单抗延迟给药。
  • 随访期间两组均未观察到新发椎体骨折。

关键数值与推荐

  • 延迟给药的标准为6个月时血清β-CTX <300 pg/mL。
  • 较低基线β-CTX:OR 0.99(95% CI 0.98-1.00;p = 0.027)。
  • 较低BMI:OR 0.60(95% CI 0.40-0.89;p = 0.012)。

临床怎么用

  • 作者认为,较低的基线骨转换和较低的BMI可能有助于识别可安全将地舒单抗给药延迟至6个月以上的印度绝经后女性。
  • 作者指出这些发现为初步结果,尚未确立长期安全性或有效性;在临床实践中采用延长给药间隔前,需要进行随访时间更长的进一步研究。

局限性

  • 这些发现为初步结果,尚未确立长期安全性或有效性。
  • 在临床实践中采用延长给药间隔前,需要进行随访时间更长的进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: This prospective study evaluated whether bone turnover markers (BTMs) and body mass index (BMI) can guide individualized denosumab dosing in postmenopausal Indian women with osteoporosis. Lower baseline β-CTX and BMI were independently associated with safe deferral of denosumab beyond 6 months, without increased fracture risk. These findings support a personalized, phenotype-based approach to denosumab therapy in low-turnover populations. PURPOSE: To evaluate whether baseline bone turnover markers (BTMs) and body mass index (BMI) can predict the safety and feasibility of extending the dosing interval of denosumab beyond six months in postmenopausal Indian women with osteoporosis. METHODS: In this prospective observational study, 56 postmenopausal women with DXA-confirmed osteoporosis were initiated on denosumab (60 mg subcutaneously).None of the participants had received prior anti-resorptive therapies. Several participants were on vitamin D supplementation, consistent with their high baseline serum 25-hydroxyvitamin D levels. Serum ß-CTX levels were measured at 6 months, guiding the timing of subsequent injections. Participants were classified into two groups: standard (dose at 6 months) and delayed (dose deferred beyond 6 months if ß-CTX <300 pg/mL). Baseline BTMs, BMI, and fracture outcomes were analysed. Multivariate logistic regression was used to identify predictors of delayed dosing. RESULTS: Twenty-eight women received delayed injections (median interval: 9.5 months). Compared to the standard group, the delayed group had significantly lower baseline ß-CTX levels (497 vs. 794 pg/mL; p < 0.001) and lower BMI (23.29 ± 2.77 vs. 25.59 ± 3.03 kg/m²; p = 0.005). Multivariate analysis showed both lower baseline ß-CTX (OR: 0.99; 95% CI: 0.98-1.00; p = 0.027) and lower BMI (OR: 0.60; 95% CI: 0.40-0.89; p = 0.012) independently predicted delayed denosumab administration. No new vertebral fractures were observed in either group during follow-up. CONCLUSIONS: Lower baseline bone turnover and lower BMI may help identify postmenopausal Indian women in whom denosumab dosing can be safely deferred beyond six months. These findings are preliminary and do not establish long-term safety or efficacy; further studies with extended follow-up are needed before adopting extended dosing intervals in clinical practice.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Jha V, Bhadada SK, Pal R, et al. Personalizing denosumab therapy in postmenopausal Indian women with osteoporosis: predictive role of bone turnover markers and body mass index in determining dosing interval. Osteoporos Int. 2025. PMID: 41020995. doi:10.1007/s00198-025-07703-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。